These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20103995)

  • 21. A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Ohshita A; Hironaka K
    Hepatogastroenterology; 2008; 55(82-83):407-11. PubMed ID: 18613376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
    Samura H; Oki E; Okumura H; Yoshida T; Kai S; Kobayashi K; Kinjo T; Mori S; Tohyama T; Ohgaki K; Kawanaka H; Makiyama A; Ureshino N; Kotaka M; Shimose T; Ando K; Saeki H; Baba H; Maehara Y; Mori M
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):285-294. PubMed ID: 32734398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
    Iwasa S; Yamada Y; Kato K; Goto A; Honma Y; Hamaguchi T; Shimada Y
    Anticancer Res; 2012 Sep; 32(9):4157-61. PubMed ID: 22993378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
    Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():131-4. PubMed ID: 16897988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
    Vanhoefer U; Harstrick A; Köhne CH; Achterrath W; Rustum YM; Seeber S; Wilke H
    J Clin Oncol; 1999 Mar; 17(3):907-13. PubMed ID: 10071283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
    Mabuchi S; Yokoi E; Owa T; Kozasa K; Yamashita M; Kobayashi E; Tomimatsu T; Yoki T; Tsutui T; Kimura T
    Int J Gynecol Cancer; 2016 Sep; 26(7):1281-7. PubMed ID: 27643650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
    Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Kaido Y; Omi H; Yokoyama Y; Mizunuma H; Kaiho M; Otsuki T; Takano T; Yaegashi N; Nishiyama H; Fujimori K; Sugiyama T
    Cancer Chemother Pharmacol; 2014 May; 73(5):895-901. PubMed ID: 24585045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
    Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
    Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [24 hour infusion of CPT-11/oral UFT/LV].
    Iwamoto S; Yoshioka K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):901-3. PubMed ID: 16835476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
    Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
    Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.